Elyse G. Seltzer
Corporate Officer/Principal chez Yale University
Profil
Elyse G.
Seltzer is currently a Member at Yale University.
Previously, she held positions as a Principal at Centocor, Inc., Johnson & Johnson, and Vicuron Pharmaceuticals LLC.
From 2006 to 2009, she served as the Chief Medical Officer at Tengion, Inc. From 2009 to 2015, she was the Vice President-Global Clinical Sciences at GSK Plc.
In 2015 to 2017, she held the position of Chief Medical Officer at Nabriva Therapeutics GmbH.
In 2017, she briefly served as the Chief Medical Officer at Nabriva Therapeutics Plc.
Currently, she is the Chief Development Officer at UroGen Pharma Ltd.
Dr. Seltzer completed her undergraduate degree at the University of Pennsylvania and obtained her doctorate from New York University School of Medicine.
Postes actifs de Elyse G. Seltzer
| Sociétés | Poste | Début |
|---|---|---|
| Yale University | Corporate Officer/Principal | - |
Anciens postes connus de Elyse G. Seltzer
| Sociétés | Poste | Fin |
|---|---|---|
| UROGEN PHARMA LTD. | Chief Tech/Sci/R&D Officer | 01/04/2020 |
| NABRIVA THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 30/09/2017 |
Nabriva Therapeutics GmbH
 Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Chief Tech/Sci/R&D Officer | 01/09/2017 |
| GSK PLC | Corporate Officer/Principal | 01/04/2015 |
| TENGION, INC. | Chief Tech/Sci/R&D Officer | 01/08/2009 |
Formation de Elyse G. Seltzer
| University of Pennsylvania | Undergraduate Degree |
| New York University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| TENGION, INC. | Health Technology |
| GSK PLC | Health Technology |
| UROGEN PHARMA LTD. | Health Technology |
| NABRIVA THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Centocor, Inc.
 Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Health Technology |
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
